Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G6 | O60733 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | FAAH | O00519 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 1.00 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromoenol Lactone SCHEMBL2060074 | 1.00 | PLA2G6 (1.00) | PLA2G6MAPK1ALDH1A1MAPTHPGD | |
| (S)-Bromoenol Lactone SCHEMBL3298296 | 1.00 | PLA2G6 (1.00) | PLA2G6MAPK1ALDH1A1MAPTHPGD | |
| (S)-Bromoenol Lactone SCHEMBL29693289 | 1.00 | PLA2G6 (1.00) | PLA2G6MAPK1ALDH1A1MAPTHPGD | |
| Bromoenol Lactone SCHEMBL29370529 | 1.00 | PLA2G6 (1.00) | PLA2G6MAPK1ALDH1A1MAPTHPGD | |
| Bromoenol Lactone SCHEMBL3302140 | 1.00 | PLA2G6 (1.00) | PLA2G6MAPK1ALDH1A1MAPTHPGD | |
| Bromoenol Lactone SCHEMBL2060073 | 1.00 | PLA2G6 (1.00) | PLA2G6MAPK1ALDH1A1MAPTHPGD | |
| Bromoenol Lactone SCHEMBL3302144 | 1.00 | PLA2G6 (1.00) | PLA2G6MAPK1ALDH1A1MAPTHPGD | |
| SCHEMBL3296491 | 0.89 | PLA2G6 (1.00) | PLA2G6MAPK1ALDH1A1MAPTHPGD | |
| SCHEMBL3296494 | 0.89 | PLA2G6 (1.00) | PLA2G6MAPK1ALDH1A1MAPTHPGD | |
| SCHEMBL3296498 | 0.89 | PLA2G6 (1.00) | PLA2G6MAPK1ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210236500-A1 | INHIBITION OF AUTOPHAGY USING PHOSPHOLIPASE A2 INHIBITORS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2021-08-05 | — | — | US | claimed |
| US-20190142835-A1 | INHIBITION OF AUTOPHAGY USING PHOSPHOLIPASE A2 INHIBITORS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2019-05-16 | — | — | US | claimed |
| US-8597893-B2 | Human phospholipase A2 epsilon | WASHINGTON UNIVERSITY IN ST. LOUIS (US) | 2013-12-03 | — | — | US | claimed |
| EP-0954303-B1 | METHODS OF TREATING MENTAL DISEASES, INFLAMMATION AND PAIN | NEUROSCIENCES RES FOUND (US) | 2011-09-21 | — | — | EP | claimed |
| US-20100183626-A1 | HUMAN PHOSPHOLIPASE A2 EPSILON | WASHINGTON UNIVERSITY IN ST. LOUIS (US) | 2010-07-22 | — | — | US | claimed |
| US-20070082946-A1 | Methods of treating mental diseases, inflammation and pain | PIOMELLI DANIELE | 2007-04-12 | — | — | US | claimed |
| US-20060079574-A1 | Methods of treating mental diseases, inflammation and pain | PIOMELLI DANIELE | 2006-04-13 | — | — | US | claimed |
| US-20050113445-A1 | Methods of treating mental diseases, inflammation and pain | PIOMELLI DANIELE (US) | 2005-05-26 | — | — | US | claimed |
| US-20030134894-A1 | Methods of treating mental diseases, inflammation and pain | PIOMELLI DANIELE (US) | 2003-07-17 | — | — | US | claimed |
| US-6525090-B1 | Inhibiting the enzyme anandamide amidohydrolase with a haloenol lactone such as 6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2-one | NEUROSCIENCES RESEARCH FOUNDATION, INC. | 2003-02-25 | — | — | US | claimed |
| EP-0954303-A4 | METHODS OF TREATING MENTAL DISEASES, INFLAMMATION AND PAIN | NEUROSCIENCES RES FOUNDATION (US) | 2002-09-18 | — | — | EP | claimed |
| EP-0954303-A2 | METHODS OF TREATING MENTAL DISEASES, INFLAMMATION AND PAIN | NEUROSCIENCES RESEARCH FOUNDATION (US) | 1999-11-10 | — | — | EP | claimed |
| US-5925672-A | Methods of treating mental diseases, inflammation and pain | NEUROSCIENCES RESEARCH FOUNDATION, INC. (US) | 1999-07-20 | — | — | US | claimed |
| WO-1998024396-A2 | METHODS OF TREATING MENTAL DISEASES, INFLAMMATION AND PAIN | NEUROSCIENCES RESEARCH FOUNDATION, INC. (US) | 1998-06-11 | — | — | WO | claimed |
| US-20230190662-A1 | Efficacy of a Gastro-Retentive Bile Acid Sequestrant Dosage Form | IRONWOOD PHARMACEUTICALS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20220370367-A1 | Gastro-Retentive Sustained-Release Oral Dosage Form of a Bile Acid Sequestrant | IRONWOOD PHARMACEUTICALS INC (US) | 2022-11-24 | — | — | US | disclosed |
| CN-114767646-A | Effects of gastric retentive bile acid sequestrant formulation | 铁木医药有限公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-1998024396-A2 | METHODS OF TREATING MENTAL DISEASES, INFLAMMATION AND PAIN | NEUROSCIENCES RESEARCH FOUNDATION, INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| US-5707821-A | Identification of phospholipase A2 inhibitors in Aβ peptide-mediated neurodegenerative disease | ATHENA NEUROSCIENCES, INC. (US) | 1998-01-13 | — | — | US | disclosed |
| US-5208244-A | Administering substituted enol lactones | WASHINGTON UNIVERSITY (US) | 1993-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134894-A1 | Methods of treating mental diseases, inflammation and pain | APEH, NAAA, FAAH2 | PLA2G6 1646/4885MAPK1 2550/4885ALDH1A1 566/4885 |
| US-20060079574-A1 | Methods of treating mental diseases, inflammation and pain | APEH, FAAH2, NAAA | PLA2G6 1840/4885MAPK1 2993/4885ALDH1A1 738/4885 |
| US-20070082946-A1 | Methods of treating mental diseases, inflammation and pain | APEH, FAAH2, NAAA | PLA2G6 1840/4885MAPK1 2993/4885ALDH1A1 738/4885 |
| US-20050113445-A1 | Methods of treating mental diseases, inflammation and pain | APEH, FAAH2, NAAA | PLA2G6 1840/4885MAPK1 2993/4885ALDH1A1 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.